Ab94914

Experimental procedures were performed as previous studies [13] . We incubated tissue sections with Wnt5b antibody (1:50, Abcam, ab94914). The intensity of Wnt5b staining was scored as following: 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3 (strong staining). The percentage scores of Wnt5b staining were assigned as following: 1 (1%-25%), 2 (26%-50%), 3 (51%-75%), and 4 (76%-100%). The above two scores were multiplied to give a final score: 0 to 12. The scores of ≥4 were defined as Wnt5b overexpression (positive expression); the scores between 1 and 4 were defined as weak expression (negative expression). The informations of PD-L1 staining were in Supplemental materials and methods. PD-L1 staining was performed by using the Dako automated staining platform according to the manufacturer's standard steps (Dako 22C3 PharmDx Assay, Dako Autostainer Link 48, Agilent, Santa Clara, CA, USA). We determined the PD-L1 expression in tumor cells by using Tumor Proportion Score (TPS). TPS was calculated as the percentage of at least 100 viable tumor cells with complete or partial membrane staining. The percentage of ≥50% was defined as PD-L1 positive expression; and that of＜50% was defined as PD-L1 positive expression.